Flamel Technologies announces FDA approval of Vazculep Flamel Technologies announced that the FDA has approved the company's New Drug Application, or NDA, for Vazculep. Vazculep Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Flamel expects to launch Vazculep in the next few months in 1 mL single use vials, and 5 mL and 10 mL pharmacy bulk package vials. The drug strength is the same in all vials at 10 mg/mL. Phenylephrine hydrochloride is used in operating rooms and is injected intravenously either as a bolus or in a dilute solution as a continuous infusion.
Perrigo and Flamel enter into exclusive licensing agreement for LiquiTime Perrigo (PRGO) and Flamel (FLML) announced that they have entered into an exclusive licensing agreement for LiquiTime(R) extended release suspension. The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.